News

Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression

Cynthia Roberts, PhD, sat down to discuss a 5-year prospective study to compare ocular stiffness parameters in, diabetes with retinopathy, diabetes without retinopathy, and normal subjects at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting

Researchers conducted a retrospective chart review to identify the clinical characteristics of the injured eyes that may be associated with visual recovery in this patient population.

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

Priorities can ensure optimal outcomes for patients diagnosed with diseases.

A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.

Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.

Amitha Domalpally, MD, PhD, discusses how disorganization of retinal inner layers affects OCT outcomes in cases of uveitic macular edema.

The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

In this investigation, the second stage of the CHAMP phase 3 trial assessed the impact of prolonging drug administration for an extra 12 months on myopia control and the occurrence of myopia rebound upon cessation of dosing.

This study also investigated the development of myopia rebound when dosing was discontinued

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear

David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Research being presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, is examining novel interventions that could address the growth in myopia.

Philip P. Storey, MD, shares the highlights of his ARVO presentation on a post hoc analysis of the pivotal TENAYA/LUCERNE trials.

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.

With the progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG)

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.